SAGE Therapeutics (SAGE) Tops Q2 EPS by 15c

SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($0.79), $0.15 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $31.66 million versus the consensus estimate of $16.75 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results